• Adicet Bio completed the last patient visit for a planned Phase 1 analysis of prula-cel in systemic lupus erythematosus.
• Results have not been presented; topline data are scheduled for September 2026, setting a near-term catalyst for the autoimmune program.
• The readout is expected to clarify prula-cel’s early safety and efficacy profile, shaping next-step development decisions.
• Separately, the FDA cleared an IND for ADI-212 in metastatic castration-resistant prostate cancer; Phase 1 enrollment is expected in 4Q 2026.
• Adicet also flagged a first in vivo CAR-T candidate for clinical entry in 2H 2027, extending its pipeline beyond ex vivo cell therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609010700BIZWIRE_USPR_____20260901_BW222277) on September 01, 2026, and is solely responsible for the information contained therein.